Humira: first licensed hidradenitis suppurativa treatment

The licence for Humira (adalimumab) has been extended to include the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults who have had an inadequate response to conventional HS therapy.

HS is a painful, chronic systemic inflammatory disorder, characterised by inflamed nodules, boils and abscesses located particularly around the groin and underarm.

Further information
View Humira drug record 
Summary of Product Characteristics
Manufacturer: AbbVie

"The approval of Humira to treat moderate to severe HS is a major step forward in supporting patients with this distressing and life-changing condition," commented Dr David Fitzgerald, consultant dermatologist at Salford Royal NHS Foundation Trust. "Patients with HS can experience immense pain and the condition often dramatically impacts their psychological wellbeing and quality of life."

The benefits and risks of long-term treatment should be evaluated regularly and if treatment is interrupted Humira may be reintroduced at the maintenance dose of 40mg per week.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more